Shareholding disclosure

Kenneth C. Griffin

Declared position

3.33%

Threshold

Crossed upwards

Timeline

Published

18.08.2020

Transaction

12.08.2020

Voting rights breakdown

Voting rights acquired3.33%

Voting rights sold0.14%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAK8E00039

Beneficial owner

Kenneth C. Griffin

Declared address

Kenneth C. Griffin, Chicago, IL

Date of transfer of equity securities: According to SIX settlement cycle

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Kenneth C. Griffin

Basilea Pharmaceutica AG, Allschwil18.08.2020TAK8E00039

Disclosure summary

Kenneth C. Griffin disclosed a holding in Basilea Pharmaceutica AG, Allschwil on the acquisition side, published by SIX Exchange Regulation on 18.08.2020, at 3.33% of voting rights. Notice category: Single shareholder.

Disclosed position

3.33%

Voting rights acquired

Voting rights acquired3.33%

Voting rights sold0.14%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Kenneth C. Griffin disclosed a holding in Basilea Pharmaceutica AG, Allschwil, published on 18.08.2020.

Publication date18.08.2020

Transaction date12.08.2020

Issuing companyBasilea Pharmaceutica AG, Allschwil

Beneficial ownerKenneth C. Griffin

Declared addressKenneth C. Griffin, Chicago, IL

CategorySingle shareholder

Voting rights acquired3.33%

Voting rights sold0.14%

Below threshold0%

ExchangeXSWX

Notification IDTAK8E00039

Conditions

Date of transfer of equity securities: According to SIX settlement cycle

Source: SIX Exchange Regulation · Publication date: 18.08.2020

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open